In addition, our recent results showed that KCNB1 polymorphisms were associated with Tumor-Node-Metastasis (TNM) progression and treatment response and suggests that such polymorphisms as biomarkers of CRC outcomes, before and during chemotherapy process [17]. The gene discussed is KCNB1; the disease is colorectal carcinoma.